An Observational Post-authorization Safety Study to Describe the Safety of Ustekinumab and Other Crohn’s Disease Treatments in a Cohort of Patients With Crohn’s Disease First published 29/01/2018 Last updated 04/09/2024 EU PAS number:EUPAS21954 Study Finalised